A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)

Inclusion criteria

• ✓. Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed.
• ✓. Subjects have received prior systemic therapy in sponsor-initiated clinical trials of cadonilimab (AK104), and this extension study is conducted after the completion of the original trial.
• ✓. Agree to proceed with the extended follow-up procedures.
• ✓. This is an observational and non-interventional clinical study, in which subjects are allowed to participate in other clinical studies at the same time.